Candel Therapeutics presented subgroup analyses from its positive Phase 3 clinical trial of CAN-2409 in intermediate-to-high-risk localized prostate cancer at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29, 2025.
The new data revealed that CAN-2409’s activity was independent of the radiation modality used in the trial, and its efficacy was maintained with moderate hypofractionated radiation. This finding is significant as moderate hypofractionated radiation offers greater convenience for patients.
The trial previously achieved its primary endpoint with a 30% improvement in disease-free survival (HR 0.7, p=0.0155) and a 38% improvement in prostate cancer-specific disease-free survival (HR 0.62, p=0.0046). At two years, pathological complete response rates were 80.4% compared to 63.6% in the control arm (p=0.0015), reinforcing the therapy's broad therapeutic potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.